Barcelona has consolidated its position as a benchmark in the international biotechnology sector. More and more biotech companies and startups are choosing the Catalan capital and its metropolitan area to develop their activities.
This sustained growth has led Barcelona to be considered the second best location in Europe for investment in biotechnology, according to the CPHI Annual Report.
This report was published on the occasion of the upcoming world’s leading pharmaceutical trade fair, CPHI Barcelona, which will be held from October 24-26, 2023 at the Gran Via de Fira exhibition center in the Catalan capital.
The study highlights that Barcelona ranks only behind the London metropolitan region as a biotech investment destination. Moreover, it is significantly ahead of biotech hubs in Switzerland, Berlin or Paris.
This ranking is based on the evaluation of productive investment opportunities for biotech companies and startups. The report was based on a macro-survey of pharmaceutical company executives around the world.
Barcelona: leader in international biotechnology
International pharmaceutical executives consulted in the study point out that Barcelona could further improve its position by increasing resources for manufacturing and by offering additional opportunities for investment, such as tax breaks or investment programs.
In particular, 53% of the executives surveyed anticipate that the implementation of such measures could make Catalonia a more attractive option than the United Kingdom and Switzerland as a European headquarters for U.S. pharmaceutical companies.
The report also highlights Spain as the sixth country in the world and the third in Europe with the highest growth potential in drug production by 2024. This rise places Spain in sixth place worldwide, surpassing countries such as the United Kingdom, Italy and France in Europe.
CPHI Barcelona’s Brand Director, Sherma Ellis-Daal, highlighted the importance of this rise in the ranking of drug-producing countries and Barcelona’s prominent place in the European Biotechnology Index.
According to Ellis-Daal, this rapid growth augurs excellent development prospects for the pharmaceutical industry in Spain in 2024 and consolidates Barcelona as a biotechnology and biosciences center of global relevance.
A world-class event
CPHI Barcelona, recognized as the leading event for the pharmaceutical industry worldwide, will be held at Fira de Barcelona’s Gran Via exhibition center from October 24-26.
The show will bring together more than 1,800 exhibitors and professionals from 171 countries, representing the entire pharmaceutical supply chain, from ingredient manufacturers to finished dose and generic suppliers, innovative pharmaceutical groups and logistics providers.
